MedPath

Carvedilol

Generic Name
Carvedilol
Brand Names
Coreg
Drug Type
Small Molecule
Chemical Formula
C24H26N2O4
CAS Number
72956-09-3
Unique Ingredient Identifier
0K47UL67F2
Background

Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication

Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions
Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
Associated Therapies
-
Clinical Trials
Related News

The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding

Phase 4
Conditions
Esophageal and Gastric Varices
Liver Cirrhosis
Interventions
Device: endoscopy
Drug: Carvedilol
First Posted Date
2016-03-01
Last Posted Date
2016-03-01
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
792
Registration Number
NCT02695732
Locations
🇨🇳

Zhongshan Hospital, Shanghai, China

The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices

Phase 4
Conditions
Gastroesophageal Varices
Cirrhosis
Interventions
Other: routine therapy
Procedure: HVPG-guided therapy
Drug: Carvedilol
First Posted Date
2015-12-23
Last Posted Date
2015-12-23
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
500
Registration Number
NCT02638415
Locations
🇨🇳

Shanghai Zhongshan Hospital, Shanghai, Shanghai, China

Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients

Not Applicable
Conditions
Heart Failure
Interventions
Drug: Nebivolol
Drug: Carvedilol
First Posted Date
2015-12-02
Last Posted Date
2018-02-05
Lead Sponsor
Dong-A University
Target Recruit Count
62
Registration Number
NCT02619526
Locations
🇰🇷

Department of Internal Medicine,Dong-A University College of Medicine, Busan, Korea, Republic of

Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices

Not Applicable
Completed
Conditions
Acute on Chronic Liver Failure
Interventions
Drug: Placebo
Drug: Carvedilol
First Posted Date
2015-10-22
Last Posted Date
2019-06-04
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Target Recruit Count
136
Registration Number
NCT02583698
Locations
🇮🇳

Institute of liver and Biliary Sciences, New Delhi, Delhi, India

Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris

Phase 4
Completed
Conditions
Stable Angina Pectoris
Interventions
Drug: Carvedilol
Drug: Atenolol
First Posted Date
2015-09-11
Last Posted Date
2015-09-11
Lead Sponsor
Gachon University Gil Medical Center
Target Recruit Count
99
Registration Number
NCT02547597
Locations
🇰🇷

Gachon University Gil Medical Center, Incheon, Korea, Republic of

Beta-blockers in Pulmonary Arterial Hypertension

Phase 2
Terminated
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Carvedilol
Drug: Placebo
First Posted Date
2015-07-23
Last Posted Date
2020-06-16
Lead Sponsor
University of Minnesota
Target Recruit Count
2
Registration Number
NCT02507011
Locations
🇺🇸

University of Minnesota Medical Center, Minneapolis, Minnesota, United States

Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding

Phase 4
Completed
Conditions
Esophageal and Gastric Varices
Interventions
Drug: carvedilol
Drug: cyanoacrylate
First Posted Date
2015-07-22
Last Posted Date
2017-08-21
Lead Sponsor
Kaohsiung Veterans General Hospital.
Target Recruit Count
121
Registration Number
NCT02504723
Locations
🇨🇳

Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

To Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices.

Not Applicable
Completed
Conditions
Cirrhosis With Esophageal Varices
Interventions
Drug: Carvedilol + Simvastatin
Drug: Carvedilol
First Posted Date
2015-06-08
Last Posted Date
2018-05-11
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Target Recruit Count
220
Registration Number
NCT02465645
Locations
🇮🇳

Institute of Liver and Biliary Sciences, New Delhi, Delhi, India

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

Not Applicable
Completed
Conditions
Hypertension
Diabetes
Interventions
Drug: Placebo
Drug: Salsalate
Drug: Carvedilol
Drug: Intralipid 20%
First Posted Date
2015-04-02
Last Posted Date
2019-01-08
Lead Sponsor
Emory University
Target Recruit Count
36
Registration Number
NCT02406586
Locations
🇺🇸

Grady Memorial Hospital, Atlanta, Georgia, United States

The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding

Phase 4
Conditions
Esophageal and Gastric Varices
Liver Cirrhosis
Hemorrhage
Interventions
Drug: Carvedilol
Drug: Propranolol
First Posted Date
2015-03-11
Last Posted Date
2015-03-11
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
480
Registration Number
NCT02385422
Locations
🇨🇳

Shanghai Zhongshan Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy